The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) closed at $4.09 down -0.49% from its previous closing price of $4.11. In other words, the price has decreased by -$0.49 from its previous closing price. On the day, 14.89 million shares were traded. RXRX stock price reached its highest trading level at $4.14 during the session, while it also had its lowest trading level at $4.05.
Ratios:
For a deeper understanding of Recursion Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.60 and its Current Ratio is at 4.60. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
On May 22, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $8.Morgan Stanley initiated its Equal-Weight rating on May 22, 2023, with a $8 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 29 ’25 when Taylor Ben R sold 21,383 shares for $4.18 per share. The transaction valued at 89,381 led to the insider holds 761,550 shares of the business.
Khan Najat sold 124,403 shares of RXRX for $548,592 on Dec 22 ’25. The Chief R&D Commercial Officer now owns 611,135 shares after completing the transaction at $4.41 per share. On Dec 29 ’25, another insider, Taylor Ben R, who serves as the Officer of the company, bought 21,383 shares for $4.18 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2131964672 and an Enterprise Value of 1554502656. For the stock, the TTM Price-to-Sale (P/S) ratio is 48.72 while its Price-to-Book (P/B) ratio in mrq is 1.92. Its current Enterprise Value per Revenue stands at 35.581 whereas that against EBITDA is -2.437.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.94, which has changed by -0.475641 over the last 52 weeks, in comparison to a change of 0.15196204 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is -13.23%, while the 200-Day Moving Average is calculated to be -19.83%.
Shares Statistics:
For the past three months, RXRX has traded an average of 41.79M shares per day and 28609270 over the past ten days. A total of 485.21M shares are outstanding, with a floating share count of 437.52M. Insiders hold about 15.93% of the company’s shares, while institutions hold 48.82% stake in the company. Shares short for RXRX as of 1765756800 were 153738758 with a Short Ratio of 3.68, compared to 1763078400 on 145661814. Therefore, it implies a Short% of Shares Outstanding of 153738758 and a Short% of Float of 31.290000000000003.
Earnings Estimates
The dynamic stock of Recursion Pharmaceuticals Inc (RXRX) is currently being evaluated by a team of 6.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.19 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.48 and -$1.73 for the fiscal current year, implying an average EPS of -$1.61. EPS for the following year is -$1.2, with 8.0 analysts recommending between -$0.63 and -$1.41.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $24.59M this quarter.It ranges from a high estimate of $46.4M to a low estimate of $17.1M. As of. The current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $4.55MFor the next quarter, 7 analysts are estimating revenue of $16.28M. There is a high estimate of $20.2M for the next quarter, whereas the lowest estimate is $10M.
A total of 9 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $85.5M, while the lowest revenue estimate was $48.35M, resulting in an average revenue estimate of $61.61M. In the same quarter a year ago, actual revenue was $58.84MBased on 9 analysts’ estimates, the company’s revenue will be $82.66M in the next fiscal year. The high estimate is $110.62M and the low estimate is $61.1M.
